Related Experiment Videos
The oncoprotein E2A-Pbx1a collaborates with Hoxa9 to acutely transform primary bone marrow cells
U Thorsteinsdottir1, J Krosl, E Kroon
1Laboratory of Molecular Genetics of Hemopoietic Stem Cells, Clinical Research Institute of Montréal, Montréal, Québec, Canada H2W 1R7.
Molecular and Cellular Biology
|August 24, 1999
Summary
The E2A-Pbx1 fusion oncoprotein collaborates with Hoxa9 to drive aggressive acute leukemia. This gene interaction promotes rapid leukemic growth and cytokine production in mouse models.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- A specific chromosomal translocation (E2A-Pbx1) is implicated in 5-10% of human acute leukemias.
- E2A-Pbx1's oncogenic activity may involve interactions with Hox proteins, also linked to leukemia development.
Purpose of the Study:
- To investigate the direct role of E2A-Pbx1 in leukemogenesis.
- To test the hypothesis that E2A-Pbx1 cooperates with Hox proteins, specifically Hoxa9.
Main Methods:
- Mouse bone marrow cells were genetically modified using retroviral gene transfer.
- Overexpression of E2A-Pbx1a and Hoxa9 was achieved in these cells.
Main Results:
- Co-expression of E2A-Pbx1a and Hoxa9 synergistically induced growth factor-independent proliferation in vitro.
- Leukemic transformation and rapid disease onset (39 days) were observed in vivo.
- Leukemic cells exhibited minimal differentiation and produced key cytokines (IL-3, G-CSF, Steel).
Conclusions:
- Hoxa9 and E2A-Pbx1a gene products collaborate to create a potent oncogenic combination.
- This collaboration leads to the development of highly aggressive acute leukemia.